Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab and Cemiplimab in B-Cell Malignancies (CLIO-1)
NCT02651662Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of odronextamab and cemiplimab in B cell lymphoma (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose limiting toxicities at 28 days, Incidence of treatment emergent adverse events at 18 months and 3 more. Started Jan 2016; status: completed.
02
Drugs
odronextamabcemiplimab
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02651662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651662.